Omalizumab inhibits allergen challenge-induced nasal response
Omalizumab inhibits allergen challenge-induced nasal response
复制标题
DOI：
10.1183/09031936.04.00024504
复制
发表时间：
2004-03-01
影响因子：
24.3
通讯作者：
Kunkel, G
中科院分区：
文献类型：
--
作者：
Hanf, G;Noga, O;Kunkel, G
血清抗原特异性免疫球蛋白（IG）E水平升高通常与过敏性呼吸道疾病相关。这项平行组、随机、双盲、安慰剂对照试验旨在研究奥马珠单抗对过敏原激发后早期鼻反应的影响，这些反应通过症状评分和鼻灌洗液（NAL）中的炎症标志物水平反映。共有23例过敏性鼻炎患者参加了这项研究，其中11例给予安慰剂，12例皮下注射奥马珠单抗。根据患者的体重和IgE水平，每隔2周或4周给予奥马珠单抗或安慰剂，总剂量为0.016 mg（.）kg（-1.）IgE（-1）（IU（.）与安慰剂相比，奥马珠单抗治疗16周可显著抑制过敏原激发诱导的鼻部症状（中位症状评分为7.0-0.5对7.0-7.0），并抑制人血清白蛋白（中位15.3-0.12 mg（.）mL（-1）版本8.2-19.7 mg（.）mL（-1））。奥马珠单抗治疗诱导肿瘤坏死因子-α水平的基础NAL显着下降，但没有变化被视为histamin.These结果表明，皮下注射单克隆抗免疫球蛋白-E抗体，奥马珠单抗，抑制过敏性鼻炎患者的过敏原挑战的鼻反应。奥马珠单抗可能为变应性鼻炎的治疗提供新的策略。
Elevated serum levels of antigen-specific immunoglobulin (Ig)E are often associated with allergic respiratory diseases. This parallel-group, randomised, double-blind, placebo-controlled trial was designed to study the influence of omalizumab on the early nasal response to allergen challenge reflected by symptom score and inflammatory marker levels in nasal lavage fluid (NAL).A total of 23 patients with allergic rhinitis took part in the study, 11 were given placebo and omalizumab was administered subcutaneously in 12. Omalizumab or placebo were given at 2- or 4-week intervals based on a patient's body weight and IgE levels to a total dose of 0.016 mg(.)kg(-1.)IgE(-1) (IU(.)mL(-1)) every 4 weeks.Compared to placebo, 16 weeks of treatment with omalizumab significantly inhibited allergen challenge-induced nasal symptoms (median symptom score 7.0-0.5 versus, 7.0-7.0) and inhibited the increase of human serum albumin (median 15.3-0.12 mg(.)mL(-1) versits 8.2-19.7 mg(.)mL(-1)) in the NAL after allergen challenge. Treatment with omalizumab induced a significant decrease in tumour necrosis factor-alpha levels in basal NAL, but no change was seen for histamine.These results indicate that subcutaneously administered monoclonal antiimmunoglobulin-E antibody, omalizumab, inhibits the nasal responses to allergen challenge of patients with allergic rhinitis. Omalizumab may provide a new strategy for the treatment of allergic rhinitis.